{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-091981","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2026-08-06T20:05:41+00:00","discovered_at":"2026-08-06T20:08:02.430271+00:00","generated_at":"2026-08-06T20:08:59.866223+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MetaVia Q2 net loss $5.3M ($0.90/sh); DA-1726 Phase 1 Part 3 all patients at highest doses; topline data Q4 2026","bullets":["Net loss of $5.3M ($0.90 per share) for Q2 2026, compared to net loss of $4.0M ($2.87 per share) in Q2 2025.","Cash and cash equivalents of $12.6M as of June 30, 2026, up from $10.3M at Dec 31, 2025; expects cash to fund operations through 2026.","All active patients in Phase 1 Part 3 of DA-1726 reached highest planned doses of 48 mg and 64 mg; 16-week topline data expected Q4 2026.","Presented data at EASL and ADA showing up to 9.1% mean weight loss at 8 weeks on 48 mg dose, with no plateau.","Planning End-of-Phase 2 meeting with FDA for vanoglipel (DA-1241) in MASH during H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-091981","json":"https://secwatch.observer/filing/0001104659-26-091981.json","markdown":"https://secwatch.observer/filing/0001104659-26-091981.md","text":"https://secwatch.observer/filing/0001104659-26-091981.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926091981/0001104659-26-091981-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926091981/mtva-20260806x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:08:59.866223+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}